Life Biosciences Inc.

Life Biosciences develops epigenetic restoration, a process that resets epigenetic marks to revert cells to a younger, healthier state. The company claims to be the only one with intellectual property covering the therapeutic use of this technology (per firm website). Its platform targets age-related diseases, with initial focus on optic neuropathies.

The firm has FDA clearance for an Investigational New Drug (IND) application for ER-100, its candidate for optic neuropathies (announced January 2026). This is the first FDA clearance for a therapeutic epigenetic restoration approach.

Life Biosciences raised an $80 million Series D in April 2026 (per firm press release, April 2026). The company does not disclose its full financing history or valuation. Ownership structure is not public.

Life Biosciences' leadership team and board are not listed on the public website. The company appointed David Guyer, M.D. to the board in November 2025 (per firm newsroom, November 2025), but no other named principals are disclosed.

The company's initial clinical program targets optic neuropathies. Preclinical work includes liver disease and ocular diseases. The broader platform aims to address multiple age-related illnesses, though specific pipeline details beyond eye and liver programs are not public.

In July 2025, Life Biosciences announced a research collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to expand its pipeline of cellular rejuvenation therapies (per firm newsroom, July 2025). No other collaborations are disclosed.

Life Biosciences is the only company with FDA clearance to advance epigenetic restoration into human clinical studies (per firm website). It also holds intellectual property covering the therapeutic use of this specific technology, creating a regulatory and IP moat.